Classic and novel roles of p53: prospects for anticancer therapy

Trends in Molecular Medicine

Volumn 13, Issue 5, 2007, Pages 192-199

  Fuster, José J ^a   Sanz González, Silvia M ^a   Moll, Ute M ^b   Andrés, Vicente ^a  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; CHLOROFUSIN; HLI 98; NUTLIN DERIVATIVE; PRIMA 1; PROTEIN MDM2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AGING; APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GENETIC TRANSCRIPTION; GENOME; HUMAN; MITOCHONDRION; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SENESCENCE; TUMOR CELL; WILD TYPE;

AGING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247597764     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.03.002     Document Type: Review

References (81)

1. Momand J., et al. The MDM2 gene amplification database. Nucleic Acids Res. 26 (1998) 3453-3459
2. Hainaut P., et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 26 (1998) 205-213
3. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13 (2006) 951-961
4. Pluquet O., and Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174 (2001) 1-15
5. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
6. Toledo F., and Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6 (2006) 909-923
7. Momand J., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
8. Honda R., et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
9. Haupt Y., et al. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
10. Kubbutat M.H.G., et al. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
11. Roth J., et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17 (1998) 554-564
12. Barak Y., et al. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12 (1993) 461-468
13. Wu X., et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7 (1993) 1126-1132
14. Montes de Oca Luna R., et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
15. Jones S.N., et al. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
16. Efeyan A., et al. Tumour biology: policing of oncogene activity by p53. Nature 443 (2006) 159
17. Pomerantz J., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92 (1998) 713-723
18. Zhang Y., et al. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 (1998) 725-734
19. Kamijo T., et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91 (1997) 649-659
20. Chen D., et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
21. Dornan D., et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004) 86-92
22. Leng R.P., et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (2003) 779-791
23. Linzer D.I., and Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17 (1979) 43-52
24. Lane D.P., and Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278 (1979) 261-263
25. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
26. Donehower L.A., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
27. Jacks T., et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4 (1994) 1-7
28. Purdie C.A., et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9 (1994) 603-609
29. Harvey M., et al. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7 (1993) 938-943
30. Venkatachalam S., et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17 (1998) 4657-4667
31. +/- mouse model in carcinogenicity testing. Toxicol. Pathol. 29 Suppl (2001) 147-154
32. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet. Cytogenet. 66 (1993) 83-92
33. Campisi J. Cancer and ageing: rival demons?. Nat. Rev. Cancer 3 (2003) 339-349
34. Tyner S.D., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415 (2002) 45-53
35. Gentry A., and Venkatachalam S. Complicating the role of p53 in aging. Aging Cell 4 (2005) 157-160
36. Maier B., et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18 (2004) 306-319
37. Gems D., and Partridge L. Insulin/IGF signalling and ageing: seeing the bigger picture. Curr. Opin. Genet. Dev. 11 (2001) 287-292
38. Keyes W.M., et al. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19 (2005) 1986-1999
39. Garcia-Cao I., et al. Super p53″ mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21 (2002) 6225-6235
40. Garcia-Cao I., et al. Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep. 7 (2006) 546-552
41. Mendrysa S.M., et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20 (2006) 16-21
42. Mendrysa S.M., and Perry M.E. Tumor suppression by p53 without accelerated aging: just enough of a good thing?. Cell Cycle 5 (2006) 714-717
43. Bourdon J.C., et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19 (2005) 2122-2137
44. Bykov V.J.N., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002) 282-288
45. Foster B.A., et al. Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999) 2507-2510
46. Takimoto R., et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 1 (2002) 47-55
47. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13 (2007) 23-31
48. Stoll R., et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40 (2001) 336-344
49. Duncan S.J., et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123 (2001) 554-560
50. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
51. Issaeva N., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
52. Krajewski M., et al. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11 (2005) 1135-1136
53. Lai Z., et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14734-14739
54. Yang Y., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
55. Martins C.P., et al. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
56. Ventura A., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
57. Xue W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
58. Caelles C., et al. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370 (1994) 220-223
59. Haupt Y., et al. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9 (1995) 2170-2183
60. Marchenko N.D., et al. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275 (2000) 16202-16212
61. Sansome C., et al. Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett. 488 (2001) 110-115
62. Moll U.M., et al. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25 (2006) 4725-4743
63. Arima Y., et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J. Biol. Chem. 280 (2005) 19166-19176
64. Dumont P., et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33 (2003) 357-365
65. Leu J.I., et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004) 443-450
66. Yamaguchi H., et al. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J. Biol. Chem. 279 (2004) 39431-39437
67. Zhao Y., et al. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 65 (2005) 3745-3750
68. Marchenko N.D., et al. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 26 (2007) 923-934
69. Mihara M., et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
70. Petros A.M., et al. Defining the p53 DNA-binding domain/Bcl-xL-binding interface using NMR. FEBS Lett. 559 (2004) 171-174
71. Tomita Y., et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281 (2006) 8600-8606
72. Strom E., et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol. 2 (2006) 474-479
73. Christophorou M.A., et al. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443 (2006) 214-217
74. Chipuk J.E., et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
75. Chipuk J.E., et al. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4 (2003) 371-381
76. Chipuk J.E., et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
77. Jiang P., et al. The Bad guy cooperates with a good Cop p53: Bad is transcriptionally up-regulated by p53 and forms Bad/p53 complex at the mitochondria to induce apoptosis. Mol. Cell. Biol. 26 (2006) 9071-9082
78. Palacios G., and Moll U.M. Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo. Oncogene 25 (2006) 6133-6139
79. Talos F., et al. Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res. 65 (2005) 9971-9981
80. Kojima K., et al. Mdm2 inhibitor nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108 (2006) 993-1000
81. Ringshausen I., et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10 (2006) 501-514